journal article·2022-03Open access

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma

Xiangling Feng, Jiaojiao Guo, Gang An, Yangbowen Wu, Zhenhao Liu, Bin Meng, Nihan He, Xinying Zhao, Shilian Chen, Yinghong Zhu, Jiliang Xia, Xin Li, Zhiyong Yu, Ruixuan Li, Guofeng Ren, Jihua Chen, Minghua Wu, Yanjuan He, Lugui Qiu, Jiaxi Zhou, Wen Zhou

Advanced Science· Volume 9· Issue 9

Abstract

Abstract It has been previously shown that (never in mitosis gene A)‐related kinase 2 (NEK2) is upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the mechanisms behind this upregulation remain poorly understood. In this study, it is found that amplification of NEK2 and hypermethylation of distal CpG islands in its promoter correlate strongly with increased NEK2 expression. Patients with NEK2 amplification have a poor rate of survival and often exhibit TP53 deletion, which is an independent prognostic factor in MM. This combination of TP53 knockout and NEK2 overexpression induces asymmetric mitosis, proliferation, drug resistance, and tumorigenic behaviors in MM in vitro and in vivo. In contrast, delivery of wild type p53 and suppression of NEK2 in TP53−/− MM cell lines inhibit tumor formation and enhance the effect of Bortezomib against MM. It is also discovered that inactivating p53 elevates NEK2 expression genetically by inducing NEK2 amplification, transcriptionally by increased activity of cell cycle‐related genes like E2F8 and epigenetically by upregulating DNA methyltransferases. Dual defects of TP53 and NEK2 may define patients with the poorest outcomes in MM with p53 inactivation, and NEK2 may serve as a novel therapeutic target in aggressive MM with p53 abnormalities.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Multiple Myeloma Research and Treatments · Protein Degradation and Inhibitors · Cancer therapeutics and mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Experimental Hematology Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education Key Laboratory of Carcinogenesis National Health and Family Planning Commission; Department of Hematology Xiangya Hospital Central South University Changsha Hunan 410028 China

Cancer Research Institute School of Basic Medical Science Central South University 110 # Xiangya street Changsha Hunan 410028 China

Xiang Ya School of Public Health Central South University Changsha Hunan 410028 China

State Key Laboratory of Experimental Hematology Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Science & Peking Union Medical College Tianjin 300041 China

Shanghai Center for Bioinformation Technology Shanghai 201203 China

The third Xiangya Hospital of Central South University Changsha Hunan 410013 China

Department of Pathology Changsha eighth hospital Changsha Hunan 410199 China

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.1056/NEJMra101144210.1056/NEJMra1011442 ↗
2. 10.1038/s41571-018-0018-y10.1038/s41571-018-0018-y ↗
3. 10.1038/nrc325710.1038/nrc3257 ↗
4. 10.1172/JCI6118810.1172/JCI61188 ↗
5. 10.1038/s41375-018-0196-810.1038/s41375-018-0196-8 ↗
6. 10.1182/blood-2006-07-03843010.1182/blood-2006-07-038430 ↗
7. 10.1182/blood.V92.3.80210.1182/blood.V92.3.802 ↗
8. 10.1038/ncb294110.1038/ncb2941 ↗
9. 10.1038/nrclinonc.2016.12210.1038/nrclinonc.2016.122 ↗
10. 10.1182/blood-2005-11-01345810.1182/blood-2005-11-013458 ↗
11. 10.1182/blood-2006-07-03870310.1182/blood-2006-07-038703 ↗
12. 10.1016/j.ccell.2017.05.01110.1016/j.ccell.2017.05.011 ↗
13. 10.1182/blood-2010-04-27959610.1182/blood-2010-04-279596 ↗
14. 10.1016/S0002-9440(10)63276-210.1016/S0002-9440(10)63276-2 ↗
15. 10.1182/blood-2004-04-136310.1182/blood-2004-04-1363 ↗
16. 10.1038/leu.2014.10210.1038/leu.2014.102 ↗
17. 10.1182/blood-2007-10-11912310.1182/blood-2007-10-119123 ↗
18. 10.1016/j.ccr.2012.12.00110.1016/j.ccr.2012.12.001 ↗
19. 10.18632/oncotarget.238810.18632/oncotarget.2388 ↗
20. 10.1038/leu.2013.38310.1038/leu.2013.383 ↗
21. 10.1091/mbc.e03-02-010810.1091/mbc.e03-02-0108 ↗
22. 10.1002/1878-0261.1264110.1002/1878-0261.12641 ↗
23. 10.1172/JCI8909210.1172/JCI89092 ↗
24. 10.1155/2015/86246110.1155/2015/862461 ↗
25. 10.1111/j.1600-0897.1991.tb01080.x10.1111/j.1600-0897.1991.tb01080.x ↗
26. 10.1126/science.aal238010.1126/science.aal2380 ↗
27. 10.1074/jbc.M113.52383710.1074/jbc.M113.523837 ↗
28. 10.1038/nrc271810.1038/nrc2718 ↗
29. 10.1128/MCB.01688-1310.1128/MCB.01688-13 ↗
30. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
31. 10.1038/nrc201210.1038/nrc2012 ↗
32. 10.1038/leu.2011.20410.1038/leu.2011.204 ↗
33. 10.1158/1078-0432.CCR-14-257610.1158/1078-0432.CCR-14-2576 ↗
34. 10.1182/blood-2016-09-73850010.1182/blood-2016-09-738500 ↗
35. 10.1038/nrc343010.1038/nrc3430 ↗
36. 10.1038/nrc269610.1038/nrc2696 ↗
37. 10.1038/cdd.2017.17210.1038/cdd.2017.172 ↗
38. 10.1158/0008-5472.CAN-20-036010.1158/0008-5472.CAN-20-0360 ↗
39. 10.1016/S0301-472X(00)00556-710.1016/S0301-472X(00)00556-7 ↗
40. 10.1073/pnas.131934111110.1073/pnas.1319341111 ↗
41. 10.1038/nmeth.331710.1038/nmeth.3317 ↗
42. 10.1038/nbt.312210.1038/nbt.3122 ↗
43. 10.1038/nprot.2016.09510.1038/nprot.2016.095 ↗
44. 10.1093/bioinformatics/btp61610.1093/bioinformatics/btp616 ↗
45. 10.1016/j.stem.2018.12.00210.1016/j.stem.2018.12.002 ↗
46. 10.1016/j.immuni.2019.01.01010.1016/j.immuni.2019.01.010 ↗
47. 10.1186/1476-4598-12-5310.1186/1476-4598-12-53 ↗
48. 10.1002/mc.2204410.1002/mc.22044 ↗